MedTrace Logo

Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients

NCT00408187 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 642

Last updated 2009-07-30

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis.

Conditions

Interventions

DRUG

voclosporin

voclosporin 0.4 mg/kg po BID

DRUG

Ciclosporin

ciclosporin 1.5 mg/kg po BID

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Aurinia Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Thomas A. Luger, Prof. Dr. · Universität Münster

  • Slawomir Majewski, Prof. Dr. · Akademia Medyczna

  • Wayne Gulliver, M.D. · NewLab Clinical Research

  • Vincent Ho, M.D. · UBC

  • Andrzej Langner, Prof. Dr. · IWOLANG

  • Wolfram Sterry, Prof. Dr. · Charite Universitatsmedizin Berlin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Canada
  • Germany
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408187 on ClinicalTrials.gov